Author of

• 12727

  +

  P3.13 - Poster Session 3 - SCLC (ID 202)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12728

    +

    P3.13-001 - Could Pretreatment PET-CT Standart Uptake Values Have a Role in the Response to Treatment and the Survival in Patients with Small Cell Lung Cancer? (ID 666)

    09:30 - 09:30  |  Author(s): O. Ercelep
    • Abstract

    Background
    It is of great importance for treatment optimization to know before the initiation of treatment the different variables that may be used to help determine the result in the oncological diseases. It has been shown in preveious studies that have been performed that standard uptake values obtained in PET-CT carried out before the treatment in various cancer types enable us to make predictions regarding the tumor’s “aggressiveness”, response to treatment and survival. In this study, we researched the predictive role of pretreatment SU values of the patients with SCLC in determining the response to treatment and the survival.

    Methods
    Ninty patients were enrolled into this study, with whom we had follow-up in our center due to SCLC, and in whom pretreatment PET-CT was performed. The SU value of primary tumor was then determined. The relationship between these values and response to treatment is examined through ROC analysis and the cut-off value, effective and thus the determination to the response to treatment is identified. In the patient group, age, gender, stage, performance status, response to treatment, and effect of SU values upon response to treatment and survival are studied.

    Results
    Ninty patients were enrolled into the study. Median follow-up period is 11 (1-43) months, and the median age is 58 (39-83). Ninety percent of patients are male and the diseases in 37% of were noted to be of limited-stage. All patients received platinum+etoposide chemotherapy once every 21 days, as median amount of treatments to cure was 6 (3-7). When ROC analysis was carried out the SU value, suitable for determining the response, is found to be 10. The sensitivity of this value is found 85.7% (CI 95%; 63-96), the specificity was found to be 61.8% (CI 95%; 49-73) (AUC: 0.783; p: 0.0001). The overall response rate (complet response+partial response) is 59.1% in the other patients, while this rate is 93.3% in patients with involvement above the cut-off value(p:<0.0001). The response rates are higher in patients with age greater than or equal to 60 years old (p:0.047). No significant relationship is found between gender, stage and performance status, and the response to treatment. In the survival analyses carried out, median disease-free survival is found to be 9 months (SE:1; 95% CI: 8-10), and median general survival was determined to be 17 months (SE:3; 95% CI: 12-22). When single and multivariate analysis are carried out, the positive impact/effect of limited-stage disease and response to treatment upon the progression-free survival is determined (p<0.05). The fact that SU value is higher than cut-off value, affects the progression-free survival positively borderline (p:0.085). As a result, this is effective upon general survival, and studied using single and multivariate analysis. It is seen that only the response rates affect the general survival positively (p<0.05).

    Conclusion
    PET-CT is used in SCLC frequently for staging purposes. The data obtained in PET-CT may have a role in determining the prognostic characteristics of the disease as well as the response to treatment.